Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant or stably-transformed bacterium encoding one or...
Reexamination Certificate
1999-01-14
2009-12-22
Swartz, Rodney P. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant or stably-transformed bacterium encoding one or...
C424S009100, C424S009200, C424S184100, C424S192100, C424S234100, C424S244100, C424S278100, C435S243000, C435S252100, C435S253400
Reexamination Certificate
active
07635486
ABSTRACT:
The present invention relates to recombinant lipidated PsaA proteins and recombinant constructs from which such lipidated PsaA proteins may be expressed. The invention relates further to lipidated PsaA proteins in which lipidation is effected by the use of a heterologous leader sequence derived from the ospA gene ofBorrelia burgdorferi,which leader sequence is joined in translational reading frame with the psaA structural gene. The invention also provides methods of preparation of lipidated PsaA proteins and use of such proteins in immunological compositions. Also provided are vaccines comprising immunogenic lipidated PsaA proteins and methods of use of such vaccines in the prevention and treatment ofS. pneumoniaeinfection.
REFERENCES:
patent: 93/10238 (1993-05-01), None
patent: 96/40718 (1996-12-01), None
Ades et al., “Intranasal Immunization with Recombinant PsaA (37kDa) Protects Mice Challenged Intranasally withStreptococcus pneumoniae,” Centers for Diseases Control and Prevention, International Conference on Emerging Infectious Diseases1998 (Abstract).
Becker et al., “Recombinant Engineering of PspA Antigen fromStreptococcus pneumoniaeas a PAM3cys-lipidated Protein Potentiates Immunogenicity for Both Parenteral and Mucosal Routes of Administration,”Vaccines97:39-44, 1997.
Bessler et al., “Synthetic lipopeptides as novel adjuvants,”Research in Immunology143(5):548-553, 1992.
Erdile et al., “OspA lipoprotein ofBorrelia burgdorferiis a mucosal immunogen and adjuvant,”Vaccine15(9):988-995, 1997.
Sampson et al., “Cloning and Nucleotide Sequence Analysis of psaA, theStreptococcus pneumoniaeGene Encoding a 37-Kilodalton Protein Homologous to Previously ReportedStreptococcussp. Adhesins,”Infection and Immunity62(1):319-324, 1994.
Sampson et al., “Limited Diversity ofStreptococcus pneumoniaepsaA among Pneumococcal Vaccine Serotypes,”Infection and Immunity65(5):1967-1971, 1997.
Talkington et al., “Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesion A (PsaA),”Microbial Pathogenesis21:17-22, 1996.
Ades Edwin W.
Carlone George M.
De Barun K.
Huebner Robert C.
Sampson Jacquelyn S.
Klarquist & Sparkman, LLP
Swartz Rodney P.
The United States of America as represented by the Department of
LandOfFree
Recombinant lipidated PsaA protein, methods of preparation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant lipidated PsaA protein, methods of preparation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant lipidated PsaA protein, methods of preparation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4117085